BioSpace News Archive

MedinCell today announces that its partner, Arthritis Innovation Corporation (AIC), who conducts and finances all development activities of F14 (MedinCell codename: mdc-CWM), has completed the patient enrollment in the first of two Phase 3 clinical studies of F14 in patients undergoing total knee replacement (TKR).

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2023 interim financial results and provided corporate updates.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 13, 2023.

AbbVie today announced the 2023-2024 class of AbbVie Immunology Scholarship recipients.

Genexine (KOSDAQ:095700, CEO Neil Warma) today announced positive topline results from the multi-center, randomized, open-label, active-controlled pivotal phase 3 study (CTJ101PGHD301) being conducted in China to evaluate the efficacy and safety of eftansomatropin alfa (Genexine’s proprietary long-acting growth hormone, also known as GX-H9) in children with growth hormone deficiency.

Zylox-Tonbridge Medical Technology Co., Ltd. announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter, a product independently developed by the Company, has received marketing approval from ANVISA.

argenx announced that members of management will participate in several upcoming investor conferences in September:

Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism.

Outlook Therapeutics, Inc. announced the U.S. Food and Drug Administration has issued a CRL to the Company’s BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

As announced in July, we are significantly restructuring Immunovia to focus on our novel next-generation test for detection of pancreatic cancer.